30-Sep-2019 - Evotec SE

Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration

Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer.

Under the terms of the collaboration agreement, Evotec received full access to the colorectal cancer (“CRC”) multi-omics data of IndivuType. The milestone of selecting three novel drug targets was achieved in less than three months.

The first set of identified targets will now be progressed towards first-in-class therapeutics for the treatment of CRC using Evotec’s multimodality drug discovery and development platforms. Four additional candidate targets identified by Indivumed’s bioinformatic and analytics will also enter the joint development programme.

Indivumed’s commitment to generating high quality and extensive cancer patient information is complementary and synergistic to Evotec’s expertise in analysing highly complex multi-omics data. Evotec will be responsible for subsequent partnering of the programmes and/or the platform.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “The rapid identification of truly novel drug targets reflects the power of our approach to precision medicine that we are pursuing together with Indivumed. The rigorous quality standards employed by Indivumed in the generation of the IndivuType multi-omics patient database enables novel insights into target-disease associations in colorectal cancer which are expected to deliver more effective treatment options.”

Prof. Dr Hartmut Juhl, Chief Executive Officer of Indivumed, said: “We are pleased with the rapid progress being made in our collaboration with Evotec to discover novel drugs that will advance the treatment of colorectal cancer (CRC) patients and potentially other cancer entities. IndivuType has enabled CRC subpopulations to be characterised based on molecular phenotypes with greater precision than has been possible before. As a result, the targets that have been identified are expected to deliver more effective and durable drugs to transform CRC patient care.”

Facts, background information, dossiers
More about Evotec
  • News

    Drug discovery with artificial intelligence

    Evotec SE announced that the Company has participated in the Series C funding round of Exscientia, the Artificial Intelligence (AI)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, ... more

    Evotec to collaborate with Ology Bioservices on antibodies against Coronavirus

    Evotec SE announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered into a partnership with Ology Bioservices, Inc. (Ology Bio) for the evaluation and analytical characterisation of antibodies against SARS-CoV-2. This work falls under a contract awarded to Ology ... more

    Evotec regains global rights to beta cell replacement therapy

    Evotec SE announced that it will regain global development and commercialisation rights to the iPSC-based programme for the treatment of diabetes developed under collaboration agreement with Sanofi.  Evotec has built a unique platform for iPSC-based drug discovery and cell therapy covering ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

More about Indivumed